Novartis/Sandoz Clear to Market Their Biosimilar Zarxio

Zarxio was approved earlier this month, the first biosimilar to be approved in the United States.

A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients.

In his ruling, U.S. District Judge Richard Seeborg, of San Francisco federal court, denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once launched, would become the first approved biosimilar in the United States.

Link to the report on Reuters:

http://reut.rs/1CDY9an